Spherix

Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, England--(BUSINESS WIRE)-- #analyst--Spherix Global Insights partners with specialist technology provider Content Catalyst to deploy their advanced portal for clients to interact with Spherix data and insights. Based in Pennsylvania, Spherix is a leading specialty market intelligence and advisory services firm, empowering customers through collaborative expertise and transformative insights to drive successful decision-making in six focused therapeutic areas. The innovative portal enables Spher.

Spherix Global Insights Partners With Content Catalyst to Launch Best-in-class Client Portal

Monroe Capital

CHICAGO--(BUSINESS WIRE)--Monroe Capital LLC (“Monroe”) today announced it acted as sole lead arranger and administrative agent on the funding of a senior credit facility to support the acquisition of Spherix Global Insights (“Spherix” or “The Company”) by private equity sponsor Susquehanna Private Capital. Additionally, Monroe provided equity capital to support the transaction and future growth of the Company. Founded in 2015 and headquartered in Exton, PA, Spherix provides pharmaceutical mark

Monroe Capital Supports Susquehanna Private Capital's Acquisition of Spherix Global Insights

Takeda Pharmaceutical

EXTON, Pa., Jan. 20, 2021 /PRNewswire/ -- Two 2020 European Medical Agency (EMA) approvals, Takeda's Entyvio SC and Celltrion Healthcare's infliximab biosimilar, Remsima SC, have captured notable shares among EU5 IBD patients, according to Spherix's recent report, RealTime Dynamix™:...

Takeda's Entyvio SC and Celltrion's Remsima SC EU5 Launches Have Benefitted from Parent Brand Reputation, New Clinical Data, and COVID-19 Restraints, According to Spherix Global Insights

EXTON, Pa., Nov. 9, 2020 /PRNewswire/ -- According to the latest report published as part of Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists (n=299) are adjusting their inflammatory bowel disease (IBD) treatment algorithms by...

Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix Global Insights

EXTON, Pa., Sept. 9, 2020 /PRNewswire/ -- According to the latest report published as part of Spherix's RealTime Dynamix™: Inflammatory Bowel Disease US service, gastroenterologists (n=100) continue to report increases in their prescribing of alternative mechanism of action (AMOA) agents,.

Recent, Positive Efficacy Data for Janssen's Stelara in Refractory Crohn's Disease Significantly Boost Patient Share for the IL-12/23 Inhibitor, According to Spherix Global Insights

EXTON, Pa., Sept. 8, 2020 /PRNewswire/ -- With the increasing prevalence of diabetes across the United States, concern about diabetic kidney disease (DKD) remains high among nephrologists, who consistently rank it as one of the disease areas with the greatest unmet need.

SGLT2 Inhibitors Could Induce a Seismic Shift in Treatment of Diabetic Kidney Disease in the US, According to Spherix Global Insights

AIM ImmunoTech Inc

Cocrystal Pharma

The major U.S. stock market averages were all tumbling close to 5% and bond yields were hitting record lows Monday following oil's plunge in the wake of the wrangling between Saudi Arabia and Russia.

3 Biotech Stocks Defying Today's Market Meltdown Thanks To COVID-19 Developments

Enzo Biochem

NanoViricides

OPKO Health

The COVID-19 outbreak has proved to be a catalyst for biotechs. Some issues that were wallowing in penny stock territory have posted stratospheric gains in the wake of efforts to develop diagnostic tests, treatments and vaccines to combat the new coronavirus.

4 Biotech Stocks Moving On COVID-19 Updates

Shares of Spherix Inc. spex soared 21% in active morning trading Friday.

Spherix stock soars after option executed for technology in patent for methods to treat coronavirus infection

Emerging Markets Report: In the Money

Emerging Markets Report:  Botox, Anthrax, and the Healing Power of Poison

Diffusion Pharmaceuticals

ElectroCore Inc

Year to date, the market has gifted investors a 9.92% return, but it remains off 5.73% from the start of the fourth quarter. While many investors are enjoying a lift in their stocks, the Ben Graham Screener, which finds net-nets, has been active.

4 Stocks Join Ben Graham Net-Net Screener Friday

News for Spherix Stock (SPEX)